Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 29 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Συντάκτης is Timotheadou, Eleni [Clear All Filters]
Opposite Prognostic Impact of Single PTEN-loss and Mutations in Early High-risk Breast Cancer..
Cancer Genomics Proteomics. 16(3), 195-206.
(2019).
(2018).
(2017).
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study..
PLoS One. 11(10), e0164013.
(2016). The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer..
BMC Neurol. 16(1), 190.
(2016). Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer..
Anticancer Res. 36(5), 2365-78.
(2016). Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia..
Mol Clin Oncol. 4(2), 211-220.
(2016).
(2016).
(2016). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study..
J Transl Med. 13, 171.
(2015). p85 protein expression is associated with poor survival in HER2-positive patients with advanced breast cancer treated with trastuzumab..
Pathol Oncol Res. 21(2), 273-82.
(2015).
(2015). The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping..
Breast. 23(3), 234-43.
(2014).
(2014).
(2014).
(2013).
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial..
PLoS One. 8(7), e69256.
(2013). Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases..
PLoS One. 8(3), e58182.
(2013).
(2013). HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy..
J Transl Med. 10, 10.
(2012). Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression..
Clin Breast Cancer. 12(3), 183-93.
(2012). Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial..
Breast Cancer Res Treat. 132(2), 609-19.
(2012).
(2012).
(2012). New agents targeting angiogenesis in glioblastoma..
Chemother Res Pract. 2011, 878912.
(2011).